Registration Deadline:
Vanderbilt Contact:
Explore other Industry Opportunities:
Asahi Kasei Pharma seeks innovative therapeutic strategies to enhance drug delivery to the kidney through conjugate linker technologies. They specifically focus on technologies capable of releasing small molecules (under 1000 Da) with terminal carboxylic acid groups.
Approaches of interest
- Linker technologies enabling carboxylic payload release in drug delivery systems
- Compounds designed for stability during circulation with selective cleavage in the kidney
- Enzyme- or pH-dependent release mechanisms of carboxylic acid release is required
Out of scope:
- Theoretical submissions without experimental evidence
- Technologies based on alcohol or amine release
Developmental stage of interest: Technologies must have in vitro or in vivoevidence demonstrating carboxylic acid release. Both existing technologies and novel methods are welcome.
Email Cameron Sargent, CTTC Licensing Officer, at cameron.sargent@vanderbilt.edu for more information.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.